2026-01-07 - Analysis Report
Okay, let's break down the provided information on UnitedHealth Group (UNH).

**0. Report Introduction**

This report analyzes the current investment potential of UnitedHealth Group Inc. (UNH) based on various financial metrics, market indicators, recent news, and analyst opinions. It compares UNH's performance against the S&P 500 (VOO) and provides a recommendation based on a holistic view.

**1. Return Rate Comparison with S&P 500 (VOO)**

*   **Ticker:** UNH
*   **Company Overview:** UnitedHealth Group Inc. is a diversified healthcare company providing health benefits and healthcare services.
*   **UNH Cumulative Return:** -20.24%
*   **VOO Cumulative Return:** 91.00%
*   **Divergence:**
    *   Current: -111.2
    *   Min: -124.6
    *   Max: 29.8
    *   Relative Divergence: 8.7

**Analysis:** UNH has significantly underperformed the S&P 500.  The divergence indicates a considerable negative difference in cumulative returns. The relative divergence, being at 8.7, suggests that the current divergence is near the lowest it has been in the analyzed period, indicating potential for recovery but also highlighting the severity of the recent underperformance.

**Alpha, Beta Analysis:**

| Year       | CAGR  | MDD   | Alpha  | Beta | Cap(B) |
|------------|-------|-------|--------|------|--------|
| 2016-2018  | 22.0% | 18.6% | 19.0%  | 0.9  | 234.1  |
| 2017-2019  | 27.0% | 18.6% | 10.0%  | 0.9  | 276.2  |
| 2018-2020  | -41.0% | 32.5% | -62.0% | 1.1  | 329.5  |
| 2019-2021  | 16.0% | 32.5% | -27.0% | 1.1  | 471.9  |
| 2020-2022  | 0.0%  | 31.5% | 2.0%   | 0.9  | 498.2  |
| 2021-2023  | 23.0% | 13.4% | 23.0%  | 0.5  | 494.7  |
| 2022-2024  | -24.0% | 23.1% | -44.0% | 0.4  | 475.4  |
| 2023-2025  | -55.0% | 58.5% | -118.0% | 0.3  | 310.2  |

**Analysis:**  The table shows a concerning trend.
    *   **Declining CAGR**: CAGR has been volatile.
    *   **Increasing MDD**: The Maximum Drawdown (MDD) is concerning. The MDD indicates the risk to principal.
    *   **Alpha is Negative**:  Alpha has been negative in many periods.
    *   **Decreasing Beta**: Beta has fallen from 1.1 to 0.3.
    *   **Falling Cap**: Market capitalization has fallen from ~500B to 310B

**2. Recent Stock Price Fluctuations**

*   **Current Close:** 336.40
*   **Last Market:**
    *   Price: 348.97
    *   Previous Close: 342.02
    *   Change: 2.03
*   **5-day SMA:** 331.89
*   **20-day SMA:** 330.90
*   **60-day SMA:** 337.34

**Analysis:** The current price is above all three SMAs, showing a possible bullish reversal.  The recent price increase (change of 2.03 in the last market) may indicate a sharp rebound. The 5-day and 20-day SMAs being close together suggests the short term trend is moving toward the longer term trend.

**3. RSI, PPO and Expected Return Analysis**

*   **MRI (Market Risk Indicator):** 0.8 (Medium Investment Recommended)
*   **RSI:** 49.62 (Neutral)
*   **PPO:** 0.19 (Neutral)
*   **Hybrid Signal:** Cash_0%_Buy 90% of cash (2 shares - Safe - MRI:0.80) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2026-01-02)
*   **Recent Relative Divergence Change:** 3.3 (+) (Short-term increase)
*   **Expected Return (%):** -236.1% (Long-term, compared to S&P 500)

**Analysis:**
    *   The MRI suggests a medium level of investment risk.
    *   The RSI and PPO indicators are relatively neutral.
    *   The hybrid signal suggests a buy, but the overall expectation is not good.
    *   The recent divergence change suggests a short-term uptick, but is dwarfed by the larger, poor expectations.
    *   The expected return indicates significantly underperformance compared to the S&P 500 over a longer investment horizon.

**4. Recent News & Significant Events (Yahoo Finance)**

*   **Negative Sentiment:** Several articles advise caution ("Don't Buy UnitedHealth Group Stock Before Jan. 27," "UnitedHealth Sinks 34.5% in a Year"). These articles likely contribute to the negative sentiment.
*   **Analyst Upgrade:**  One article highlights an "Outperform" rating from Evercore ISI, providing a contrasting view.
*   **Strategic Divestiture:** The potential sale of Optum UK suggests strategic shifts within the company.
*   **Hedge Fund Activity:**  David Tepper selling UNH stock could also be a point of concern for some investors.

**Analysis:**  The news is mixed.  While there's an analyst upgrade, the prevailing sentiment appears negative, with articles highlighting price declines and cautioning against immediate investment. Strategic divestitures can be viewed positively or negatively depending on the context and perceived value.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean = 1.96)
*   **Opinions:** 26
*   **Target Price (avg/high/low):** 392.73 / 440.00 / 280.00
*   **Recent Rating Changes:** No specific changes are provided.

**Analysis:** Despite recent negative news, the analyst consensus remains a "Buy" with a significant target price upside. The average target price of $392.73 suggests a considerable potential increase from the current price.

**5. Recent Earnings Analysis:**

| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2025-10-28 | 2.59  | 113.16 B$  |
| 2025-08-11 | 3.76  | 111.62 B$  |
| 2025-05-07 | 6.9   | 109.58 B$  |
| 2024-11-04 | 6.56  | 100.82 B$  |
| 2025-10-28 | 6.56  | 100.82 B$  |

**Analysis:** Revenue growth appears consistent, but EPS (Earnings Per Share) has been quite volatile, with a recent downtick.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue     | Profit Margin |
|--------------|-------------|---------------|
| 2025-09-30   | $113.16B    | 18.24%        |
| 2025-06-30   | $111.62B    | 17.93%        |
| 2025-03-31   | $109.58B    | 21.70%        |
| 2024-12-31   | $100.81B    | 21.14%        |
| 2024-09-30   | $100.82B    | 22.84%        |

**Capital and Profitability:**

| Quarter      | Equity      | ROE    |
|--------------|-------------|--------|
| 2025-09-30   | $95.79B    | 2.45%  |
| 2025-06-30   | $94.72B    | 3.60%  |
| 2025-03-31   | $95.04B    | 6.62%  |
| 2024-12-31   | $92.66B    | 5.98%  |
| 2024-09-30   | $94.53B    | 6.41%  |

**Analysis:**  Revenue is consistently growing quarter by quarter, indicating strong sales. Profit margins show variability. ROE (Return on Equity) has decreased in recent quarters, suggesting the company is generating less profit from shareholder equity.

**7. Comprehensive Analysis (Summary)**

*   **Underperformance:** UNH has significantly underperformed the S&P 500, with a large negative divergence.
*   **Technicals:** Recent price action is positive, and the stock trades above the SMAs, indicating a possible short-term bullish trend.
*   **Indicators:** RSI and PPO are neutral.
*   **News:** Recent news is mixed, with some negative sentiment balanced by an analyst upgrade and a strategic divestiture.
*   **Analyst Opinion:** Analyst consensus is still "Buy" with a substantial target price upside.
*   **Earnings:** Revenue growth is consistent, but EPS and ROE have been volatile/decreasing.

**Overall Assessment:**

The current situation is complex. While the analyst consensus and short-term technical indicators suggest a potential buying opportunity, the significant underperformance compared to the S&P 500, negative news sentiment, decreasing ROE, and decreasing market cap warrant caution. The very negative "Expected Return" is concerning.

**Recommendation:**

Given the mixed signals and significant underperformance, a **HOLD** or **CAUTIOUS BUY** approach is advisable. Investors should closely monitor UNH's performance in the coming quarters, paying particular attention to the drivers behind the negative sentiment and the company's ability to improve its ROE and overall profitability. Waiting for more clarity and consistent positive trends may be prudent before making a significant investment.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.